Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain

Pain Medicine

Volumn 4, Issue 1, 2003, Pages 21-30

  Gammaitoni, Arnold R ^a   Galer, Bradley S ^a,b   Lacouture, Peter ^c   Domingos, John ^a   Schlagheck, Thomas ^a  

^a ENDO PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Magidom Discovery LLC   (United States)

Author keywords

Low back pain; Oxycodone acetaminophen; Pain; Quality of life; Safety

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PERCOCET; TRAMADOL; BENZODIAZEPINE; OPIATE; OXYCODONE;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; LIVER TOXICITY; LOW BACK PAIN; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; OPEN STUDY; OUTCOMES RESEARCH; PAIN ASSESSMENT; PHYSICAL DISABILITY; PHYSICAL EXAMINATION; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RISK ASSESSMENT; SCORING SYSTEM; SEDATION; SOMNOLENCE; STATISTICAL ANALYSIS; VOMITING; AGE DISTRIBUTION; DRUG SCREENING; LUMBAR SPINE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT WITHDRAWAL;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; FEMALE; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; OXYCODONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0141452077     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4637.2003.03002.x     Document Type: Article

References (39)

1. Guo HR, Tanaka S, Halperin WE, et al. Back pain prevalence in US industry and estimates of lost workdays. Am J Public Health 1999;89:1029-35.
2. Aronoff GM, Dupay D. Evaluation and management of back pain: preventing disability. J Back Musculoskeletal Rehab 1997;9:109-24.
3. Dillane JB, Fre J, Kalton G. Acute back syndrome: A study from general practice. BMJ 1966;2:82-4.
4. Svensson HO, Andersson GBJ. Low-back pain in 40- to 47-year-old men: Work history and work environment factors. Spine 1983;8:272-6.
5. Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine 1995;20:11-9.
6. Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain 2000;84:95-103.
7. Nickel R, Egle UT, Eysel P, et al. Health-related quality of life and somatization in patients with long-term low back pain: A prospective study with 109 patients. Spine 2001;26:2271-7.
8. Snook SH, Webster BS. The cost of disability. Clin Orthop 1987;221:77-84.
9. Aronoff GM, Dupuy DN. Evaluation and management of back pain: Preventing disability. In: Aronoff GM, editor. Evaluation and treatment of chronic pain. 3rd edition. Philadelphia: Lippincott, Williams & Wilkins; 1999. p. 247-57.
10. Deyo RA. Drug therapy for back pain: Which drugs help which patients? Spine 1996;21:2840-50.
11. Fields HL, Martin JB. Pain: Pathophysiology and management. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principles of internal medicine. 14th edition. New York: McGraw-Hill Medical Publishing Division; 2001. p. 53-67.
12. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
13. Porter RW, Ralston SH. Pharmacological management of back pain syndromes. Drugs 1994;48:189-98.
14. Weinblatt ME. Drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Scand J Rheumatol Suppl 1989;83:7-10.
15. Strumpf M, Linstedt U, Wielbalck A, et al. [Treatment of low back pain - significance, principles and danger.] Schmerz 2001;15:453-60. German.
16. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis -related pain: Placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60.
17. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
18. Brown RL, Fleming MF, Patterson JJ. Chronic opioid analgesic therapy for chronic low back pain. J Am Board Fam Pract 1996;9:191-204.
19. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review. Anesth Analg 2000;90:933-7.
20. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic pain. Clin J Pain 1999;15:179-83.
21. Jamison RN, Raymond SA, Slawsby EA, et al. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine 1998;23:2591-600.
22. Salzman RT, Roberts MS, Wild J, et al. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-relcase form for the purpose of titrating to stable pain control? J Pain Symptom Manage 1999;18:271-9.
23. Watson CPN. The medical treatment of postherpetic neuralgia: antidepressants, anticonvulsants, opioids, and practical guidelines for management. In: Watson CPN, Gershon AA, eds. Herpes Zoster and Postherpetic Neuralgia. 2nd edition. New York, NY: Elsevier Science; 2001. p. 243-54.
24. Portenoy RK. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990; 5(suppl):S46-62.
25. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986-25:171-86.
26. Savage SR. Long-term opioid therapy: Assessment of consequences and risks. J Pain Symptom Manage 1996;11:274-86.
27. Gammaitoni AR, Davis MW. Comparison of the pharmacokinetics of oxycodone administered in three Percocet® formulations. J Clin Pharmacol 2002;42:192-7.
28. Poyhia R, Seppala T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992;33:617-21.
29. Poyhia R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993;8:63-7.
30. Cooper SA, Precheur H, Rauch D, et al. Evaluation of oxycodone and actaminophen in treatment of postoperative dental pain. Oral Surg Oral Med Oral Pathol 1980;50:496-501.
31. Palangio M, Morris E, Doyle RT Jr, et al. Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain. Clin Ther 2002;24:87-99.
32. Bolesta S, Haber SL. Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors. Ann Pharmacother 2002;36: 331-3.
33. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology 1997;48:332-8.
34. Daltroy LH, Cats-Baril WL, Katz JN, et al. The North American Spine Society lumbar spine outcome assessment instrument: Reliability and validity tests. Spine 1996;21:741-9.
35. Hunsaker FG, Cioffi DA, Amadio PC, et al. The American Academy of Orthopaedic Surgeons outcomes instruments: Normative values from the general population. J Bone Joint Surg Am 2002;84:208-15.
36. Atlas SJ, Deyo RA. Evaluating and managing acute low back pain in the primary care setting. J Gen Intern Med 2001;16:120-31.
37. Beaver WT. Combination analgesics. Am J Med 1984;77:38-53.
38. Sunshine A, Olson NZ, Zighelboim I, et al. Ketoprofen, acetaminophen plus oxycodone, and acetaminophen in the relief of postoperative pain. Clin Pharmacol Ther 1993;54:546-55.
39. Royal M, Jenson M, Gunyea I, et al. Retrospective assessment of frequency of dosing of sustained release opiate preparations in chronic pain patients. Presented at the 21st Annual Scientific Meeting of the American Pain Society, Baltimore, March 14-17, 2002.